Heiden seeks: The new AMAG CEO outlines a strategy of cost-reduction and acquisition
This article was originally published in Scrip
Executive Summary
William Heiden joined AMAG Pharmaceuticals as president and CEO in May 2012, at a time when the public company was struggling to find its way forward. Since then he's been paving a path toward profitability.